🔥The 9th Round of Easy Loan, Earn $40 Reward is in progress❗️ ⏰ Promotion Period: January 15th - Feburary 15th, 2025 👉 Register now and check more details at gate.io/campaigns/358

Happy to share my last paper concerning our FFCD PRODIGE DURIGAST trial that evaluated FOLFIRI plus immunotherapy in second-line of oeso-gastric adenocarcinoma showing a significant efficacy of this combo ! jamanetwork.com/journals/jamao…

C est parti pour les cours intensifs de la Blake Hooker au #mame de Tours 16 et 17 mai 2024. Merci pr Thierry Lecomte pour l organisation. CHRU de Tours #CRGA FFCD Dijon La Ligue contre le cancer Institut national du cancer

#asco #ASCO24 🇫🇷🥐 Retrouvez-nous à Chicago sur notre stand de 9h à 17h : 🔻 Publisher Pavillon : # 35139

New French guidelines for colon cancer are now online Non-metastatic colon cancer: French Intergroup Clinical Practice Guidelines for diagnosis, treatments, and follow-u… pubmed.ncbi.nlm.nih.gov/38383162/

C est parti pour une très belle « journée de printemps » à Saint Étienne grâce à l impeccable organisation du pr Jean-Marc Phelip et de son comité scientifique. #fetedelaffcd #cestlété😎

Day #2 Excellent 👏👏overview re: IO Therapy in MSI-S #colorectal #cancer and the promise but remaining challenges: ESMO - Eur. Oncology #esmoambassadors #ESMOGI24 with Keynote speaker Myriam Chalabi #immunotherapy #cancer #cancerresearch

Always a pleasure to speak with Tougeron David at #ESMOGI24 on the POCHI trial of pembro with xelox and bev in pMMR/MSS #colorectal #cancer and Dr Chalabi’s keynote talk on #immunotherapy MSS #CRC Visit VJOncology.com to see other highlights in GI cancers! ESMO - Eur. Oncology

Watch out : ENGIC in progress. Great organisation in Munich around #ESMOGI24 . Europe in academic GI research it is right now !!! #aio #bgdo Fédération Francophone de Cancérologie Digestive @GroupeUnicancer#gono #ttd #nordic #leedsgroup … 🇪🇺 🇩🇪🇧🇪🇮🇹🇪🇸🇳🇱🇩🇰🇸🇪🇫🇷

Pembrolizumab Plus Bevacizumab/CAPOX Yields Responses in pMMR/MSS mCRC With High TILs #crcsm #oncology #ESMOGI24 ESMO - Eur. Oncology Tougeron David onclive.com/view/pembroliz…

⭐️ESMO recommendation for genomic testing in solid cancer 👇🏻 check out annalsofoncology.org/article/S0923-… OncoAlert

How to select pMMR/MSS with sensitivity to IO combined with chemo ?

On a tous quelque chose à faire pour l environnement 🌍. La lettre de la FFCD se digitalise à 💯 %. Ici 👉bit.ly/Lettre_Juin2024

Hello everyone 👋 Dario Trapani Rille and I are working on a Lancet Oncology commission on how cancer care can be more patient focused. Our work is studying the psychosocial aspects of #MedEd. We'd be so 🙏 if you could help with this short survey! docs.google.com/forms/d/e/1FAI…

Happy to share my last paper done with Pr René Adam and many collegues showing a hepatic secondary resection rate of 21% in mCRC treated in second line with folfiri aflibercept Resection of colorectal liver metastases with second-line aflibercept ... sciencedirect.com/science/articl…

Happy to share my last paper with Harry Sokol team showing that Faecalibacterium prausnitzii is associated with clinical response to immune checkpoint inhibitors in oeso-gastric adenocarcinoma in DURIGAST trial pubmed.ncbi.nlm.nih.gov/39454892/

Happy to share the paper of Marie Muller showing low efficacy of olaparib in PDAC with non-BRCA-HRD pathogenic variants pubmed.ncbi.nlm.nih.gov/39366210/

Randrian et al. Tougeron David CHU de Poitiers, in the METACER study, showed that brain metastasizes from gastrointestinal cancers have a poor prognosis. #JNO Read more:link.springer.com/article/10.100…

New #JITC article: Interplay between sarcopenia, GDF-15, and the efficacy of nivolumab plus ipilimumab in patients with mismatch repair deficient metastatic colorectal cancer: final survival analysis of the phase II GERCOR NIPICOL study bit.ly/44VkjqA Tougeron David

Great catching up with Tougeron David shares key insights from #ESMOGI25 on advancing gastric & esophageal cancer care 🔬 RATIONALE-306 subgroup analysis in advanced ESCC 🎯 Biomarker-driven treatment selection strategies 📈 Most practice-changing trials from this year's